Timing Matters in Immunotherapy

Research suggests that administering immunotherapy in the morning significantly improves cancer control and survival rates.

This is linked to the body's circadian rhythm, which influences immune system efficiency at different times of the day.

Morning immunotherapy may leverage higher concentrations of T-cells in the lymphatic system, optimizing the immune response.

The timing appears crucial despite the long half-life of immunotherapy drugs, possibly due to initial immune system activation peaks.

Further research is needed to confirm these findings and explore the mechanisms involved.